Targeting Peripheral Serotonin for the Treatment of Pulmonary Arterial Hypertension

May 16, 2022 @ 1:30 pm 2:00 pm PDT

Presenter: Mandy MacLean, PhD
University of Strathclyde
Institute of Pharmacy and Biomedical Sciences
United Kingdom

Professor MacLean’s research has focused on the role of serotonin in the development of PAH, as well as sex differences, and the influence of estrogen metabolism and signaling in pulmonary arterial hypertension. She is the Principal Investigator for two ongoing Program Grants awarded by the British Heart Foundation for the study of PAH and was elected to the Council of the Academy of Medical Sciences in 2020.

Presenter: Oksana Shlobin, MD
Medical Director, Pulmonary Hypertension Program
Falls Church, Virginia

Dr. Shlobin is the Director of Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital and the Director of the Inova Pulmonary Vascular Disease Program. She is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine and Associate Clinical Professor of Medicine at the University of Virginia. Her research interests include pulmonary hypertension and interstitial lung disease, and she has co-authored many publications, including original research manuscripts and book chapters.

Join Altavant Sciences in Theater 1 on Monday, May 16th from 1:30 – 2:00 p.m. PDT for a program that will include an expert overview of the role of serotonin in the pathogenesis of pulmonary arterial hypertension, and an overview of the Phase 2b clinical trial for the investigation of Altavant’s lead candidate, rodatristat ethyl for the treatment of WHO Group 1 pulmonary arterial hypertension.

PAH is currently treated with vasodilators, which offer benefit but fail to address the underlying pulmonary vessel remodeling believed to be responsible for the disease’s high morbidity and mortality. Beyond the central nervous system, serotonin has numerous regulatory roles in the periphery to maintain normal physiological function, but its dysregulation can be a causative and persistent contributor to PAH. Altavant Sciences is developing a peripherally targeted inhibitor of serotonin biosynthesis to address the pathological effects of excessive serotonin signaling in pulmonary arterial hypertension.

Altavant Sciences News & Events